Match!
Elaine Xiang
Harvard University
TolerabilityMelphalanDaratumumabRegimenMedicine
2Publications
0Citations
What is this?
Publications 2
Newest
#1Elaine Xiang (Harvard University)
#2Jian Ni (Brigham and Women's Hospital)
Last. Anne M. McDonnell (Brigham and Women's Hospital)H-Index: 8
view all 6 authors...
IntroductionFor multiple myeloma patients who respond to primary therapy, autologous hematopoietic stem cell transplant (HSCT) is considered standard of care with high-dose melphalan for transplant candidates. There are now two different melphalan formulations available, including a propylene glycol containing (PG-MEL) product and a propylene glycol-free (PG-free MEL) product. Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the t...
Source
#1Elaine Xiang (Harvard University)
#2Hillary Prescott (Harvard University)
Last. Houry Leblebjian (Harvard University)H-Index: 7
view all 7 authors...
Introduction: Multiple Myeloma (MM) is a hematologic cancer caused by malignant plasma cells. Daratumumab is an immunoglobin G1 kappa human monoclonal antibody that targets CD38 antigen which is a cell surface glycoprotein highly expressed on myeloma cells. Daratumumab is FDA approved as monotherapy and in combination with dexamethasone and lenalidomide, bortezomib or pomalidomide in relapsed/refractory MM. Daratumumab is typically dosed: 16mg/kg weekly (Weeks 1-8), then 16mg/kg biweekly (Weeks ...
Source
1